Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders

Lario Therapeutics United States of America United Kingdom

New prestigious grants support Lario's unique portfolio of calcium channel programmesIndication expansion into Parkinson's disease, and PTSD (post-traumatic stress disorders)Builds on prior support from The Michael J. Fox Foundation and further validates Lario's precision neuroscience platformas promising disease-modifying target.

CaV2.3 (encoded by CACNA1E) has been implicated by genetic and functional studies in multiple neurological and neuropsychiatric disorders, including developmental and genetic epilepsies – notably, developmental encephalopathy epilepsy (DEE) – as well as Parkinson's disease, and post-traumatic stress disorder.

Selective modulation of CaV2.3 offers a precision-medicine approach that targets pathological neuronal dysfunction while avoiding the broader effects of non-selective calcium channel inhibition. Lario Therapeutics' core programme focuses on selective CaV2.3 inhibitors for severe developmental encephalopathies (DEEs) and is being expanded into additional indications.

For more information about Lario Therapeutics please visit lariotx.com.

View original content:https://www.prnewswire.co.uk/news-releases/lario-therapeutics-awarded-2-4m-by-the-michael-j-fox-foundation-and-wellcome-to-expand-neuronal-calcium-channel-platform-across-cns-disorders-302691685.html